
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos is poised to experience significant growth and success thanks to its pioneering minimally invasive glaucoma surgery procedures, the success of its iStent trabecular micro-bypass stent, and its expanding product portfolio and comprehensive platform. The company's iDose TR travoprost intracameral implant for glaucoma and sustained release will likely see strong demand, and the recent survey data show encouraging approval trends for approval of the product. The potential for future competition in the cross-linking market and potential LCD impacts could be offset by the company's successful launch of Epioxa and growing revenue.
Bears say
Glaukos is facing potential challenges in the near future due to proposed LCD changes for their iDose TR product, which may significantly impact sales volumes. Additionally, the combined burden of requiring patients to fail two medications and SLT before being eligible for iDose TR treatment may limit the potential efficacy and reach of the product. This may lead to lower revenues and slower growth for the company. Furthermore, the high percentage of iDose TR volumes being performed concomitantly with cataract surgery may also be impacted by potential LCD changes, creating uncertainty for future revenue growth. Additionally, while the company's Epioxa product may provide some upside in the future, there are concerns about limited payor coverage and the prior authorization process for the product. Overall, these factors may lead to a potential decrease in revenue and performance for Glaukos in the coming years.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares